

# Bela Ozsvari

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/10551021/bela-ozsvari-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36

papers

1,828

citations

22

h-index

37

g-index

37

ext. papers

2,193

ext. citations

5.1

avg, IF

4.51

L-index

#	Paper	IF	Citations
36	High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 740720	5.3	7
35	First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds. <i>Aging</i> , <b>2020</b> , 12, 10162-10179	5.6	10
34	A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1528	5.3	5
33	Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine). <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 615	5.3	26
32	Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: Mito-stemness and ribo-stemness features. <i>Aging</i> , <b>2019</b> , 11, 4801-4835	5.6	7
31	Azithromycin and Roxithromycin define a new family of "senolytic" drugs that target senescent human fibroblasts. <i>Aging</i> , <b>2018</b> , 10, 3294-3307	5.6	53
30	Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs). <i>Aging</i> , <b>2018</b> , 10, 229-240	5.6	22
29	A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX. <i>Cell Cycle</i> , <b>2018</b> , 17, 2091-2100	4.7	36
28	Mannich Curcuminoids as Potent Anticancer Agents. <i>Archiv Der Pharmazie</i> , <b>2017</b> , 350, e1700005	4.3	18
27	Mitoriboscins: Mitochondrial-based therapeutics targeting cancer stem cells (CSCs), bacteria and pathogenic yeast. <i>Oncotarget</i> , <b>2017</b> , 8, 67457-67472	3.3	23
26	Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity. <i>Oncotarget</i> , <b>2017</b> , 8, 9868-9884	3.3	35
25	A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis. <i>Aging</i> , <b>2017</b> , 9, 2098-2116	5.6	12
24	Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy. <i>Aging</i> , <b>2017</b> , 9, 2610-2628	5.6	32
23	Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs). <i>Oncotarget</i> , <b>2017</b> , 8, 78340-78350	3.3	22
22	The Curcumin Analog C-150, Influencing NF- $\kappa$ B, UPR and Akt/Notch Pathways Has Potent Anticancer Activity In Vitro and In Vivo. <i>PLoS ONE</i> , <b>2016</b> , 11, e0149832	3.7	29
21	Graphene oxide selectively targets cancer stem cells, across multiple tumor types: implications for non-toxic cancer treatment, via "differentiation-based nano-therapy". <i>Oncotarget</i> , <b>2015</b> , 6, 3553-62	3.3	150
20	Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells. <i>Oncotarget</i> , <b>2015</b> , 6, 14777-95	3.3	175

19	Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. <i>Oncotarget</i> , <b>2015</b> , 6, 4569-84	3.3	309
18	Doxycycline down-regulates DNA-PK and radiosensitizes tumor initiating cells: Implications for more effective radiation therapy. <i>Oncotarget</i> , <b>2015</b> , 6, 14005-25	3.3	76
17	Targeting tumor-initiating cells: eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. <i>Oncotarget</i> , <b>2015</b> , 6, 4585-601	3.3	46
16	Dissecting tumor metabolic heterogeneity: Telomerase and large cell size metabolically define a sub-population of stem-like, mitochondrial-rich, cancer cells. <i>Oncotarget</i> , <b>2015</b> , 6, 21892-905	3.3	33
15	Mitochondrial mass, a new metabolic biomarker for stem-like cancer cells: Understanding WNT/FGF-driven anabolic signaling. <i>Oncotarget</i> , <b>2015</b> , 6, 30453-71	3.3	84
14	Compounds blocking methylglyoxal-induced protein modification and brain endothelial injury. <i>Archives of Medical Research</i> , <b>2014</b> , 45, 753-64	6.6	20
13	Extracellular deposition of matrilin-2 controls the timing of the myogenic program during muscle regeneration. <i>Journal of Cell Science</i> , <b>2014</b> , 127, 3240-56	5.3	14
12	Sucrose esters increase drug penetration, but do not inhibit p-glycoprotein in caco-2 intestinal epithelial cells. <i>Journal of Pharmaceutical Sciences</i> , <b>2014</b> , 103, 3107-19	3.9	31
11	Extracellular deposition of matrilin-2 controls the timing of the myogenic program during muscle regeneration. <i>Development (Cambridge)</i> , <b>2014</b> , 141, e1606-e1606	6.6	
10	Lipid droplet binding thalidomide analogs activate endoplasmic reticulum stress and suppress hepatocellular carcinoma in a chemically induced transgenic mouse model. <i>Lipids in Health and Disease</i> , <b>2013</b> , 12, 175	4.4	8
9	Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability. <i>Cytotechnology</i> , <b>2013</b> , 65, 395-406	2.2	27
8	Kinetic analysis of the toxicity of pharmaceutical excipients Cremophor EL and RH40 on endothelial and epithelial cells. <i>Journal of Pharmaceutical Sciences</i> , <b>2013</b> , 102, 1173-81	3.9	73
7	Aromatic sulfonamides containing a condensed piperidine moiety as potential oxidative stress-inducing anticancer agents. <i>Medicinal Chemistry</i> , <b>2013</b> , 9, 911-9	1.8	7
6	The effect of sucrose esters on a culture model of the nasal barrier. <i>Toxicology in Vitro</i> , <b>2012</b> , 26, 445-54	3.6	42
5	Trypsin reduces pancreatic ductal bicarbonate secretion by inhibiting CFTR Cl <sup>-</sup> channels and luminal anion exchangers. <i>Gastroenterology</i> , <b>2011</b> , 141, 2228-2239.e6	13.3	50
4	A cell-microelectronic sensing technique for the screening of cytoprotective compounds. <i>International Journal of Molecular Medicine</i> , <b>2010</b> , 25, 525-30	4.4	30
3	Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. <i>Nature Genetics</i> , <b>2008</b> , 40, 78-82	36.3	291
2	The guinea pig pancreas secretes a single trypsinogen isoform, which is defective in autoactivation. <i>Pancreas</i> , <b>2008</b> , 37, 182-8	2.6	6

- 1 Controversies in the role of SLC26 anion exchangers in pancreatic ductal bicarbonate secretion. 2.6 7  
*Pancreas*, **2008**, 37, 232-4